Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/217696
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Multitarget Virtual Screening for Drug Repurposing in COVID19

AutorSorzano, Carlos Óscar S.; Crisman, Enrique CSIC; Carazo, José M.; León, Rafael CSIC ORCID
Palabras claveCOVID-19
Virtual drug screening
Structural biology
Fecha de publicación17-jul-2020
EditorChemRxiv
ResumenTherapeutic or preventive research for coronavirus SARS-CoV2 is an extremely active topic of research since its outbreak in January 2020. In this paper we report the results from a virtual drug screening analysis that, to the best of our knowledge, is the widest work in terms of target proteins and compound library. Our study was focused on the repur- posing of currently commercialized drugs, and especially those that can interact with multiple viral proteins and several binding sites within each protein. Additionally, we performed a second virtual screening analysis in which we compared our results to the predicted binding a nities for the drugs currently in clinical trials. We show that the best molecules in our screening compares favourably to those in clinical trials, suggesting their suitability for therapeutic or preventive applications.Therapeutic or preventive research for coronavirus SARS-CoV2 is an extremely active topic of research since its outbreak in January 2020. In this paper we report the results from a virtual drug screening analysis that, to the best of our knowledge, is the widest work in terms of target proteins and compound library. Our study was focused on the repur- posing of currently commercialized drugs, and especially those that can interact with multiple viral proteins and several binding sites within each protein. Additionally, we performed a second virtual screening analysis in which we compared our results to the predicted binding a nities for the drugs currently in clinical trials. We show that the best molecules in our screening compares favourably to those in clinical trials, suggesting their suitability for therapeutic or preventive applications.
Versión del editorhttps://doi.org/10.26434/chemrxiv.12652997.v2
URIhttp://hdl.handle.net/10261/217696
DOI10.26434/chemrxiv.12652997.v2
Aparece en las colecciones: (PTI Salud Global) Colección Especial COVID-19
(CNB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
DrugRepurposing.pdf483,99 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

215
checked on 23-abr-2024

Download(s)

177
checked on 23-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons